Research Associate I/II, Proteomics (Contractor)
Vividion Therapeutics, Inc
Summary
The successful candidate will have a high level of organization and attention to detail, as well as hands-on experience with techniques such as cell culture, transfections, high-throughput screening, in vivo tissue processing, chemical biology, and/or proteomics. This position will help discover novel small-molecule ligands of protein targets through the execution of screens using our novel mass spectrometry-based proteomics platforms.
Job description
Job Summary
The successful candidate will have a high level of organization and attention to detail, as well as hands-on experience with techniques such as cell culture, transfections, high-throughput screening, in vivo tissue processing, chemical biology, and/or proteomics. This position will help discover novel small-molecule ligands of protein targets through the execution of screens using our novel mass spectrometry-based proteomics platforms.
Requirements
- B.S. in Biology or related field with 1-4 years of laboratory experience
- Ability to reliably implement complex laboratory protocols in multi-well format
- Must have experience with cell culture
- Experience with proteomics sample prep, liquid-handling robots and lab automation equipment is a plus
- Excellent organization and communication skills; attention to detail and good documentation habits
- Be a team player and strong individual contributor, flexible, and able to handle multiple tasks and deliver high quality results under tight timelines
Requirements
- B.S. in Biology or related field
- 1-4 years of laboratory experience
- Ability to reliably implement complex laboratory protocols in multi-well format
- Must have experience with cell culture
- Excellent organization and communication skills
- Attention to detail and good documentation habits
- Team player and strong individual contributor
- Flexible and able to handle multiple tasks under tight timelines
Company overview
Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. Founded in 2017 and based in San Diego, California, the company leverages a cutting-edge covalent-first chemoproteomics platform spun out of The Scripps Research Institute. Vividion's innovative approach enables the discovery of novel therapeutics that bind challenging disease-causing protein targets previously considered 'undruggable'. The company is advancing a diversified pipeline of selective small molecule therapeutics targeting key proteins in oncology and immunology, with multiple clinical-stage programs including VVD-037 (a KEAP1 activator) and VVD-642 (a RAS-PI3Kα inhibitor) for non-small cell lung cancer and other RAS-driven cancers. With 201-500 employees, Vividion combines deep expertise in chemical biology and synthetic chemistry to develop first and best-in-class medicines for patients with devastating diseases.